MASH cirrhosis treatment, fibrosis reversal, and population screening were cited by experts as hepatology's biggest gaps.
Zobair Younossi, MD, MPH, FACG, FACP, AGAF
Advertisement
Articles by Zobair Younossi, MD, MPH, FACG, FACP, AGAF
Low risk stratification rates are fueling a looming MASH cost crisis, but earlier treatment access could bend the curve, said Zobair M. Younossi, MD.
Advertisement
Latest Updated Articles
- Curing Chronic Hepatitis C With Sofosbuvir-Based Regimens
October 23rd 2014
Advertisement
Advertisement
Trending on AJMC
1
Wildfire Smoke Raises Asthma Risks as Fires Worsen Air Quality Across North America
2
Judge Denies Preliminary Injunction in Medicaid Work Requirements Case
3
Acoramidis Attenuates Decline in Heart Failure–Related Health Status in ATTR-CM
4
Can Oral Semaglutide Reduce Heavy Drinking in Alcohol Use Disorder?
5